Xywav
| Combination of | |
|---|---|
| Calcium oxybate | CNS depressant |
| Magnesium oxybate | CNS depressant |
| Potassium oxybate | CNS depressant |
| Sodium oxybate | CNS depressant |
| Clinical data | |
| Trade names | Xywav |
| License data | |
| Routes of administration |
By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Xywav, is a medication used to treat cataplexy or excessive daytime sleepiness (EDS). It contains a mixture of oxybate salts, namely Calcium oxybate, Magnesium Oxybate, Potassium Oxybate, and Sodium Oxybate. It is taken by mouth.
Manufactured by the Jazz Pharmaceuticals company, it was approved for medical use in the United States in July 2020.
Medical uses
Xywav is indicated for the treatment of cataplexy in people aged seven years of age and older with narcolepsy.
In August 2021, the U.S. Food and Drug Administration (FDA) approved Xywav for the treatment of idiopathic hypersomnia.
Side Effects
Breathing Problems
Slowed breathing, Trouble breathing, Sleep apnea
Mental Health Problems
Confusion, Hallucination, Unusual or disturbing thoughts (abnormal thinking), Anxiety, Depression, Suicidal Thoughts or actions, Increased tiredness, feelings of guilt or worthlessness, Difficulty concentrating
Other
Society and culture
Legal status
Xywav was granted orphan drug designation in November 1994 by the U.S. Food and Drug Administration (FDA). The FDA granted the approval of Xywav to Jazz Pharmaceuticals plc in August 2021.
Other names
In the testing phase of the drug, it was known as JZP-258